These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366 [TBL] [Abstract][Full Text] [Related]
25. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598 [TBL] [Abstract][Full Text] [Related]
26. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study. Welty FK; Lewis SJ; Friday KE; Cain VA; Anzalone DA J Womens Health (Larchmt); 2016 Jan; 25(1):50-6. PubMed ID: 26539650 [TBL] [Abstract][Full Text] [Related]
27. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P; J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362 [TBL] [Abstract][Full Text] [Related]
28. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126 [TBL] [Abstract][Full Text] [Related]
29. Pitavastatin: clinical effects from the LIVES Study. Teramoto T Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644 [TBL] [Abstract][Full Text] [Related]
32. Review of efficacy of rosuvastatin 5 mg. Teramoto T; Watkins C Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472 [TBL] [Abstract][Full Text] [Related]
33. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? Athyros VG; Kakafika A; Tziomalos K; Karagiannis A; Mikhailidis DP Expert Opin Investig Drugs; 2008 Apr; 17(4):445-9. PubMed ID: 18363511 [TBL] [Abstract][Full Text] [Related]
34. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475 [TBL] [Abstract][Full Text] [Related]
35. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Rader DJ; Davidson MH; Caplan RJ; Pears JS Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340 [TBL] [Abstract][Full Text] [Related]
36. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Mohammadpour AH; Akhlaghi F Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137 [TBL] [Abstract][Full Text] [Related]
38. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio. Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP; J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584 [TBL] [Abstract][Full Text] [Related]
39. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB; Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446 [TBL] [Abstract][Full Text] [Related]
40. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice. Bell TA; Graham MJ; Lee RG; Mullick AE; Fu W; Norris D; Crooke RM J Lipid Res; 2013 Oct; 54(10):2647-57. PubMed ID: 23801661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]